Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

被引：0
|
作者：
Metz, D. C. [1 ]
Liu, E. [2 ]
Joish, V. N. [3 ]
Huynh, L. [4 ]
Cheng, M. [4 ]
Kunzweiler, C. [4 ]
Duh, M. S. [4 ]
Giacalone, S. [3 ]
Lapuerta, P. [3 ]
Morse, M. A. [5 ]
机构：
[1] Neuroendocrine Tumor Ctr Penn Med, Philadelphia, PA USA
[2] Rocky Mt Canc Ctr, Neuroendocrine Inst, Denver, CO USA
[3] Lexicon Pharmaceut Inc, The Woodlands, TX USA
[4] Anal Grp, Boston, MA USA
[5] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC USA
来源：
NEUROENDOCRINOLOGY | 2020年 / 110卷
关键词：
neuroendocrine tumor; carcinoid syndrome; telotristat ethyl; serotonin; tumor growth; progression-free survival;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H21
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [1] Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl
    Lapuerta, P.
    Kulke, M. H.
    Caplin, M.
    Bergsland, E.
    Anthony, L.
    Oeberg, K.
    Pavel, M.
    Hoersch, D.
    O'Dorisio, T. M.
    Dillon, J. S.
    Kassler-Taub, K.
    Jiang, W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival
    Wu, T.
    Zhang, P.
    Wang, G.
    ANNALS OF ONCOLOGY, 2025, 36 (03) : 340 - 340
  • [3] Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
    Metz, David C.
    Liu, Eric
    Joish, Vijay N.
    Huynh, Lynn
    Totev, Todor, I
    Duh, Mei Sheng
    Seth, Kiernan
    Giacalone, Susan
    Lapuerta, Pablo
    Morse, Michael A.
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 9713 - 9719
  • [4] Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer
    Ponce, Sara E. Beltran
    Erickson, Beth A.
    Hall, William A.
    Bedi, Meena
    Martens, Michael J.
    Siker, Malika
    Thomas, James
    George, Ben
    Ludwig, Kirk
    Peterson, Carrie
    Ridolfi, Timothy
    Longo, John M.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (01) : 185 - 196
  • [5] Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome
    Anthony, Lowell B.
    Kulke, Matthew H.
    Caplin, Martyn E.
    Bergsland, Emily
    Oberg, Kiell
    Pavel, Marianne
    Hoersch, Dieter
    Warner, Richard R. P.
    O'Dorisio, Thomas M.
    Dillon, Joseph S.
    Lapuerta, Pablo
    Kassler-Taub, Kenneth
    Liang, Wenjun
    ONCOLOGIST, 2019, 24 (08): : E662 - E670
  • [6] Long-term outcomes with pimavanserin for psychosis in clinical practice
    Akbar, Umer
    Friedman, Joseph H.
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2022, 6
  • [7] Gamma Knife surgery for parasellar meningiomas: long-term results including complications, predictive factors, and progression-free survival Clinical article
    Williams, Brian J.
    Yen, Chun Po
    Starke, Robert M.
    Basina, Bhuvaneswara
    Nguyen, James
    Rainey, Jessica
    Sherman, Jonathan H.
    Schlesinger, David
    Sheehan, Jason P.
    JOURNAL OF NEUROSURGERY, 2011, 114 (06) : 1571 - 1577
  • [8] Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma
    Dyer, Brandon A.
    Kahn, Leonel A.
    Matin, Mahan
    Bold, Richard J.
    Tanaka, Michael I.
    Monjazeb, Arta M.
    CUREUS, 2015, 7 (12):
  • [9] Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice
    Robinson, Andrew G.
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2303 - 2308
  • [10] OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS
    Aissaoui, A.
    Bin Sawad, A.
    Turkistani, F.
    Aissaoui, N.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
12345